Study of Optimal Replacement of Thyroxine in the ElDerly (SORTED): protocol for a mixed methods feasibility study to assess the clinical utility of lower dose thyroxine in elderly hypothyroid patients: study protocol for a randomized controlled trial

Trials

Salman Razvi¹  Lorna Ingoe¹  Tim Rapley²  Vicky Ryan²  Simon Pearce³  Scott Wilkes² 

[1] Department of Endocrinology, Queen Elizabeth Hospital, Gateshead, NE9 6SX, UK;Institute of Health & Society, Newcastle University, Baddiley Clark Building, Richardson Road, Newcastle upon Tyne, NE2 4AX, UK;Institute of Genetic Medicine, International Centre for Life, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK

关键词: Randomized controlled trial;    Feasibility;    Thyroxine;    Cardiovascular disease;    Primary health care;    General practice;    Ageing;    Hypothyroidism;   

Others  :  1094475
DOI  :  10.1186/1745-6215-14-83

 received in 2012-09-17, accepted in 2013-02-28,  发布年份 2013

【 摘 要 】

Background

The population of the UK is ageing. There is compelling evidence that thyroid stimulating hormone distribution levels increase with age. Currently, in UK clinical practice elderly hypothyroid patients are treated with levothyroxine to lower their thyroid stimulating hormone levels to a standard non-age-related range. Evidence suggests that mortality is negatively associated with thyroid stimulating hormone levels. We report the protocol of a feasibility study working towards a full-scale randomized controlled trial to test whether lower dose levothyroxine has beneficial cardiovascular outcomes in the oldest old.

Methods/design

SORTED is a mixed methods study with three components:

SORTED A: A feasibility study of a dual-center single-blinded randomized controlled trial of elderly hypothyroid patients currently treated with levothyroxine.

Setting: Patients will be recruited from 20 general practices and two hospital trust endocrine units in Northumberland, Tyne and Wear.

Participants: Target recruitment of 50 elderly hypothyroid patients currently treated with levothyroxine, identified in both primary and secondary care settings.

Intervention: Reduced dose of levothyroxine to achieve an elevated serum thyroid stimulating hormone (target range 4.1 to 8.0 mU/L) versus standard levothyroxine replacement (target range 0.4 to 4.0 mU/L).

Randomization: Using random permuted blocks, in a ratio of 1:1, randomization will be carried out by Newcastle Clinical Trials Unit.

Outcomes: Study feasibility (recruitment and retention rates and medication compliance), acceptability of the trial design, assessment of mobility and falls risk, and change in cardiovascular risk factors.

SORTED B: Qualitative study using in-depth interviews to understand patients’ willingness to take part in a randomized controlled trial and participants’ experience of the intervention.

SORTED C: Retrospective cohort study of 400 treated hypothyroid patients aged 80 years or over registered in 2008 in primary care practices, studying their 4-year cardiovascular outcomes to inform the power of SORTED II.

Discussion

This is a study to evaluate the feasibility of conducting a randomized controlled trial in elderly hypothyroid patients in general practice and hospital settings. The results will inform the design of the definitive SORTED II trial to evaluate the effects of lower dose thyroxine in elderly hypothyroid patients.

Trial registration

Current Controlled Trials http://ISRCTN16043724 webcite

【 授权许可】

   
2013 Wilkes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]UK National Statistics [http://www.statistics.gov.uk/hub/population/population-change/population-projections/index.html webcite]
• [2]Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA: Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002, 87(2):489.
• [3]Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F: The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol 1977, 7(6):481-493.
• [4]Surks MI, Hollowell JG: Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007, 92(12):4575-4582.
• [5]Parle J, Roberts L, Wilson S, Pattison H, Roalfe A, Haque MS: A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. J Clin Endocrinol Metab 2010, 95(8):3623-3632.
• [6]Biondi B, Cooper DS: The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008, 29(1):76-131.
• [7]Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG: Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004, 292(21):2591-2599.
• [8]Simonsick EM, Newman AB, Ferrucci L, Satterfield S, Harris TB, Rodondi N: Subclinical hypothyroidism and functional mobility in older adults. Arch Intern Med 2009, 169(21):2011-2017.
• [9]Bauer DC, Rodondi N, Stone KL, Hillier TA, Study of Osteoporotic Fractures Research Group: Universities of California (San Francisco), Kaiser Permanente Center for Health Research P: Thyroid hormone use, hyperthyroidism and mortality in older women. Am J Med 2007, 120(4):343-349.
• [10]Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH: The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. J Clin Endocrinol Metab 2008, 93(8):2998-3007.
• [11]Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J: Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008, 148(11):832-845.
• [12]Cooper DS: Thyroid disease in the oldest old: the exception to the rule. JAMA 2004, 292(21):2651-2654.
• [13]Allahabadia A, Razvi S, Abraham P, Franklyn J: Diagnosis and treatment of primary hypothyroidism. BMJ 2009, 338:b725.
• [14]Lancaster GA, Dodd S, Williamson PR: Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004, 10(2):307-312.
• [15]The EQ-5D health questionnaire [http://www.euroqol.org/eq-5d.html webcite]
• [16]McMillan C, Bradley C, Razvi S, Weaver J: Evaluation of new measures of the impact of hypothyroidism on quality of life and symptoms: the ThyDQoL and ThySRQ. Value Health 2008, 11(2):285-294.
• [17]Stapleton C, Hough P, Bull K, Hill K, Greenwood K, Oldmeadow L: A 4-item falls-risk screening tool for sub-acute and residential care: The first step in falls prevention. Australas J Ageing 2009, 28(3):139-143.
• [18]EMC Mercury Pharmaceuticals [http://www.medicines.org.uk/EMC/medicine/27214/PIL/Eltroxin+50+and+100+micrograms+Tablets/ webcite]
• [19]Medicines for Human use in Clinical Trials [http://www.uk-legislation.hmso.gov.uk/si/si2004/20041031.htm webcite]
• [20]Strauss ACJ: Basics of Qualitative Research. Grounded Theory Procedures and Techniques. Sage: Newbury Park; 1990.
• [21]Denzin NK, Lincoln YS: Handbook of Qualitative Research. London: Sage Publications; 1994.
• [22]ICH Harmonised Tripartite Guideline for Good Clinical Practice [http://www.ich.org webcite]
• [23]Department of Health: Research Governance Framework for Health and Social Care. 2nd edition. 2005. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4108962 webcite